Chen Xinyuan,Li Zhi.Updates in diagnosis and treatment of inflammatory myofibroblastic tumor in children[J].Journal of Clinical Pediatric Surgery,2023,22(03):296-300.[doi:10.3760/cma.j.cn101785-202204073-018]
儿童炎性肌纤维母细胞瘤诊治进展
- Title:
- Updates in diagnosis and treatment of inflammatory myofibroblastic tumor in children
- Keywords:
- Inflammatory Myofibroblastic Tumor; Inflammatory Pseudotumor; Target Therapy; ALK Inhibitors
- 摘要:
- 炎性肌纤维母细胞瘤(inflammatory myofibroblastic tumor,IMT)是一种罕见的间叶组织肿瘤,儿童较成人多见,其临床表现与肿瘤的占位效应和局部炎症有关,并因解剖位置而异。手术是IMT的主要治疗方法,但术后易复发,肿瘤对常规放化疗均不敏感。近年来随着新一代测序技术的应用与靶向药物的不断开发,我们对LMT的组织学特点和生物学行为有了更深入的了解,IMT的诊治策略也发生了很大改变。本文旨在回顾IMT的病因、病理特点和诊治方法,阐述IMT治疗的最新进展以及一些未来可能应用于临床的治疗方法,为儿童IMT的诊断和治疗提供参考。
- Abstract:
- Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal tumor in children.Clinical manifestations of IMTs are associated with mass tumor effect and local inflammatory responses and differ according to tumor location.Surgical resection is an optimal treatment option with a high recurrence rate.IMT remains insensitive to chemoradiotherapy.With rapid developments of next-generation sequencing and targeted drug dosing,clinicians have acquired a deeper understanding of its histological characteristics and biological behaviors.Managements and evaluation strategies for this disease have greatly changed.Etiologies,clinical characteristics and treatments of IMT were summarized for optimal managements of IMT in children.
参考文献/References:
[1] Li YP,Han WW,He LJ,et al.Inflammatory myofibroblastic tumor after treatment of Wilms tumor in a 6-year-old boy:a case report and literature review[J].Urology,2021,149:e25-e28.DOI:10.1016/j.urology.2020.11.012.
[2] Lindberg MR,Cassarino DS,Gardner J,et al.Soft tissue tumors:a practical and comprehensive guide to sarcomas and benign neoplasms[M].Diagnostic Pathology-Soft Tissue Tumors,2019,88/99:114-119.
[3] Lahcen K,Wilfried C,Abibou N,et al.Inflammatory maxillary myofibroblastic tumor:a case report[J].Saudi J Med Pharm Sci,2020,6(7):480-484.DOI:10.36348/sjmps.2020.v06i07.001.
[4] Zhao JL,Han DJ,Gao MZ,et al.Inflammatory myofibroblastic tumor of the neck with thyroid invasion:a case report and literature review[J].Gland Surg,2020,9(4):1042-1047.DOI:10.21037/gs-20-355.
[5] Filips A,Maurer MH,Montani M,et al.Inflammatory myofibroblastic tumor of the liver:a case report and review of literature[J].World J Hepatol,2020,12(4):170-183.DOI:10.4254/wjh.v12.i4.170.
[6] Armstrong V,Khazeni K,Rosenberg A,et al.Inflammatory pseudotumor secondary to urachal cyst:a challenging clinical case report[J].Int J Surg Case Rep,2020,66:360-364.DOI:10.1016/j.ijscr.2019.12.029.
[7] Zarei S,Abdul-Karim FW,Chase DM,et al.Uterine inflammatory myofibroblastic tumor showing an atypical ALK signal pattern by FISH and DES-ALK fusion by RNA sequencing:a case report[J].Int J Gynecol Pathol,2020,39(2):152-156.DOI:10.1097/PGP.0000000000000588.
[8] Mamone G,Di Piazza A,Carollo V,et al.Imaging of primary malignant tumors in non-cirrhotic liver[J].Diagn Interv Imaging,2020,101(9):519-535.DOI:10.1016/j.diii.2020.01.010.
[9] Lee JC,Li CF,Huang HY,et al.ALK oncoproteins in atypical inflammatory myofibroblastic tumours:novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma[J].J Pathol,2017,241(3):316-323.DOI:10.1002/path.4836.
[10] Coffin CM,Hornick JL,Fletcher CDM.Inflammatory myofibroblastic tumor:comparison of clinicopathologic,histologic,and immunohistochemical features including ALK expression in atypical and aggressive cases[J].Am J Surg Pathol,2007,31(4):509-520.DOI:10.1097/01.pas.0000213393.57322.c7.
[11] Bennett JA,Nardi V,Rouzbahman M,et al.Inflammatory myofibroblastic tumor of the uterus:a clinicopathological,immunohistochemical,and molecular analysis of 13 cases highlighting their broad morphologic spectrum[J].Mod Pathol,2017,30(10):1489-1503.DOI:10.1038/modpathol.2017.69.
[12] Devereaux KA,Fitzpatrick MB,Hartinger S,et al.Pregnancy-associated inflammatory myofibroblastic tumors of the uterus are clinically distinct and highly enriched for TIMP3-ALK and THBS1-ALK fusions[J].Am J Surg Pathol,2020,44(7):970-981.DOI:10.1097/PAS.0000000000001481.
[13] 王一真,任素珍.儿童炎性肌纤维母细胞瘤11例临床病理分析[J].诊断病理学杂志,2012,19(5):355-357.DOI:10.3969/j.issn.1007-8096.2012.05.009. Wang YZ,Ren SZ.Inflammatory myofibroblastic tumor in children:a clinicopathologic study of 11 cases[J].Chin J Diagn Pathol,2012,19(5):355-357.DOI:10.3969/j.issn.1007-8096.2012.05.009.
[14] Siemion K,Reszec-Gielazyn J,Kisluk J,et al.What do we know about inflammatory myofibroblastic tumors?-A systematic review[J].Adv Med Sci,2022,67(1):129-138.DOI:10.1016/j.advms.2022.02.002.
[15] Bennett JA,Croce S,Pesci A,et al.Inflammatory myofibroblastic tumor of the uterus:an immunohistochemical study of 23 cases[J].Am J Surg Pathol,2020,44(11):1441-1449.DOI:10.1097/PAS.0000000000001525.
[16] Dalton BGA,Thomas PG,Sharp NE,et al.Inflammatory myofibroblastic tumors in children[J].J Pediatr Surg,2016,51(4):541-544.DOI:10.1016/j.jpedsurg.2015.11.015.
[17] Pulford K,Morris SW,Mason DY.Anaplastic lymphoma kinase proteins and malignancy[J].Curr Opin Hematol,2001,8(4):231-236.DOI:10.1097/00062752-200107000-00009.
[18] Chan JK,Cheuk W,Shimizu M.Anaplastic lymphoma kinase expression in inflammatory pseudotumors[J].Am J Surg Pathol,2001,25(6):761-768.DOI:10.1097/00000478-200106000-00007.
[19] Debelenko LV,Arthur DC,Pack SD,et al.Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor[J].Lab Invest,2003,83(9):1255-1265.DOI:10.1097/01.lab.0000088856.49388.ea.
[20] Ma ZG,Hill DA,Collins MH,et al.Fusion of ALK to the ran-binding protein 2(RANBP2) gene in inflammatory myofibroblastic tumor[J].Genes Chromosomes Cancer,2003,37(1):98-105.DOI:10.1002/gcc.10177.
[21] Bridge JA,Kanamori M,Ma ZG,et al.Fusion of the ALK gene to the clathrin heavy chain gene,CLTC,in inflammatory myofibroblastic tumor[J].Am J Pathol,2001,159(2):411-415.DOI:10.1016/S0002-9440(10)61711-7.
[22] Mano H.ALKoma:a cancer subtype with a shared target[J].Cancer Discov,2012,2(6):495-502.DOI:10.1158/2159-8290.CD-12-0009.
[23] Voena C,Chiarle R.The battle against ALK resistance:successes and setbacks[J].Expert Opin Investig Drugs,2012,21(12):1751-1754.DOI:10.1517/13543784.2012.717930.
[24] Kerr DA,Thompson LDR,Tafe LJ,et al.Clinicopathologic and genomic characterization of inflammatory myofibroblastic tumors of the head and neck:highlighting a novel fusion and potential diagnostic pitfall[J].Am J Surg Pathol,2021,45(12):1707-1719.DOI:10.1097/PAS.0000000000001735.
[25] WHO Classification of Tumours Editorial Board.WHO classification of tumours:soft tissue and bone tumours[M].5th ed.Geneva:World Health Organization,2020:109-111.
[26] Doski JJ,Priebe CJ Jr,Driessnack M,et al.Corticosteroids in the management of unresected plasma cell granuloma (inflammatory pseudotumor) of the lung[J].J Pediatr Surg,1991,26(9):1064-1066.DOI:10.1016/0022-3468(91)90674-i.
[27] Panigada S,Sacco O,Girosi D,et al.Corticosteroids may favor proliferation of thoracic inflammatory myofibroblastic tumors[J].Pediatr Pulmonol,2014,49(3):E109-E111.DOI:10.1002/ppul.22977.
[28] Germanidis G,Xanthakis I,Tsitouridis I,et al.Regression of inflammatory myofibroblastic tumor of the gastrointestinal tract under infliximab treatment[J].Dig Dis Sci,2005,50(2):262-265.DOI:10.1007/s10620-005-1593-1.
[29] Grünholz D,Appiani F,Abarca C,et al.Peritoneal myofibroblastic tumor successfully treated with infliximab:report of one case[J].Rev Med Chil,2015,143(7):943-947.DOI:10.4067/s0034-98872015000700017.
[30] Casanova M,Brennan B,Alaggio R,et al.Inflammatory myofibroblastic tumor:the experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG)[J].Eur J Cancer,2020,127:123-129.DOI:10.1016/j.ejca.2019.12.021.
[31] Butrynski JE,D’Adamo DR,Hornick JL,et al.Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor[J].N Engl J Med,2010,363(18):1727-1733.DOI:10.1056/NEJMoa1007056.
[32] Pearson ADJ,Barry E,Mossé YP,et al.Second paediatric strategy forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies:ACCELERATE in collaboration with the European medicines agency with the participation of the food and drug administration[J].Eur J Cancer,2021,157:198-213.DOI:10.1016/j.ejca.2021.08.022.
[33] Sch?ffski P,Sufliarsky J,Gelderblom H,et al.Crizotinib in patients with advanced,inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE):a multicentre,single-drug,prospective,non-randomised phase 2 trial[J].Lancet Respir Med,2018,6(6):431-441.DOI:10.1016/S2213-2600(18)30116-4.
[34] Mossé YP,Voss SD,Lim MS,et al.Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor:a children’s oncology group study[J].J Clin Oncol,2017,35(28):3215-3221.DOI:10.1200/JCO.2017.73.4830.
[35] Trahair T,Gifford AJ,Fordham A,et al.Crizotinib and surgery for long-term disease control in children and adolescents with ALK-positive inflammatory myofibroblastic tumors[J].JCO Precis Oncol,2019,3:1-11.DOI:10.1200/PO.18.00297.
[36] Yuan C,Ma MJ,Parker JV,et al.Metastatic anaplastic lymphoma kinase-1(ALK-1)-rearranged inflammatory myofibroblastic sarcoma to the brain with leptomeningeal involvement:favorable response to serial ALK inhibitors:a case report[J].Am J Case Rep,2017,18:799-804.DOI:10.12659/ajcr.903698.
[37] Mansfield AS,Murphy SJ,Harris FR,et al.Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib[J].Ann Oncol,2016,27(11):2111-2117.DOI:10.1093/annonc/mdw405.
[38] Mittal A,Gupta A,Rastogi S,et al.Near-complete response to low-dose ceritinib in recurrent infantile inflammatory myofibroblastic tumour[J].Ecancermedicalscience,2021,15:1215.DOI:10.3332/ecancer.2021.1215.
[39] Kong XT,Pan PC,Sun HY,et al.Drug discovery targeting anaplastic lymphoma kinase (ALK)[J].J Med Chem,2019,62(24):10927-10954.DOI:10.1021/acs.jmedchem.9b00446.
[40] Liu DZ,Offin M,Harnicar S,et al.Entrectinib:an orally available,selective tyrosine kinase inhibitor for the treatment of NTRK,ROS1,and ALK fusion-positive solid tumors[J].Ther Clin Risk Manag,2018,14:1247-1252.DOI:10.2147/TCRM.S147381.
[41] Shankar A,Kurzawinski T,Ross E,et al.Treatment outcome with a selective RET tyrosine kinase inhibitor selpercatinib in children with multiple endocrine neoplasia type 2 and advanced medullary thyroid carcinoma[J].Eur J Cancer,2021,158:38-46.DOI:10.1016/j.ejca.2021.09.012.
[42] Cha YJ,Shim HS.PD-L1 expression and CD8+tumor-infiltrating lymphocytes are associated with ALK rearrangement and clinicopathological features in inflammatory myofibroblastic tumors[J].Oncotarget,2017,8(52):89465-89474.DOI:10.18632/oncotarget.20948.
[43] Cottrell TR,Duong AT,Gocke CD,et al.PD-L1 expression in inflammatory myofibroblastic tumors[J].Mod Pathol,2018,31(7):1155-1163.DOI:10.1038/s41379-018-0034-6.
[44] Fordham AM,Xie JH,Gifford AJ,et al.CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma[J].Br J Cancer,2020,123(7):1101-1113.DOI:10.1038/s41416-020-0996-2.
备注/Memo
收稿日期:2022-4-24。
基金项目:国家自然科学基金(81400579)
通讯作者:李智,Email:lizhimdphd@163.com